Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACP-204 open-label extension in adults with Lewy body dementia psychosis
2025-521711-39-00Phase 3Authorised
- Sponsor
- Acadia Pharmaceuticals
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of remlifanserin in Lewy body dementia (LBD), sponsored by Acadia Pharmaceuticals. Primary endpoint: Treatment-emergent adverse events. Planned start May 2026; status: authorised.
02
Drugs
remlifanserin
03
Conditions
Lewy body dementia (LBD)
Beyond the preview
Go deeper on 2025-521711-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521711-39-00.